First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy

26/03/2020 - 08:35

Ce communiqué de presse est seulement disponible en anglais.